Annual Report

The report highlights 4SC's 2021 clinical-stage focus, including completion of the 190-patient RESMAIN recruitment target and reaching 80% of events needed for unblinding. It describes a US-$17.25 million settlement of Immunic's remaining royalty obligation, payable half in cash and half in shares. While preparing the report, the Management and Supervisory Boards decided to discontinue domatinostat development and focus resources on resminostat.